Q-omics provides the consensus-scored TXNRD3 profile across patient tissues and cancer cell-line models. TXNRD3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TXNRD3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TXNRD3 RNA expression shows 19,357 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, COAD, and ACC as cancer lineages where TXNRD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXNRD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXNRD3 survival associations across molecular data types. TXNRD3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXNRD3 RNA expression–survival associations across cancer types. High TXNRD3 expression shows unfavorable associations in UCEC, PAAD, ACC, MESO and THCA, but favorable associations in DLBC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for TXNRD3 RNA expression.
This table summarizes TXNRD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TXNRD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXNRD3 shows lower tumor expression in THCA and higher tumor expression in COAD, HNSC, BLCA, LIHC and READ. The COAD box plot shows higher TXNRD3 RNA expression in tumor versus normal tissue (log2 FC = +1.273, t-test p < 0.001).
This table shows molecular features associated with TXNRD3 in patient tissues and cancer cell lines. In patient samples, TXNRD3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TXNRD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
